Gene symbol | FURIN | Synonyms | FUR, PACE, PCSK3, SPC1 | Type of gene | protein-coding | |
Chromosome | 15 | Map location | 15q26.1 | dbXrefs | Entrez:5045 MIM:136950 HGNC:HGNC:8568 Ensembl:ENSG00000140564 AllianceGenome:HGNC:8568 | |
Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
Description | furin, paired basic amino acid cleaving enzyme |
Gene symbol | TGFB1 | Synonyms | CED, DPD1, IBDIMDE, LAP, TGF-beta1, TGFB, TGFbeta | Type of gene | protein-coding | |
Chromosome | 19 | Map location | 19q13.2 | dbXrefs | Entrez:7040 MIM:190180 HGNC:HGNC:11766 Ensembl:ENSG00000105329 AllianceGenome:HGNC:11766 | |
Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
Description | transforming growth factor beta 1 |
Gene symbol | TGFB2 | Synonyms | G-TSF, LDS4, TGF-beta2 | Type of gene | protein-coding | |
Chromosome | 1 | Map location | 1q41 | dbXrefs | Entrez:7042 MIM:190220 HGNC:HGNC:11768 Ensembl:ENSG00000092969 AllianceGenome:HGNC:11768 | |
Description | transforming growth factor beta 2 |
GTO ID | GTC0139 |
Trial ID | NCT01551745 |
Disease | Ovarian Cancer |
Altered gene | FURIN|TGFB1|TGFB2 |
Therapeutic/Target gene | Target gene |
Therapy | shRNA |
Treatment | Vigil|FANG Vaccine |
Co-treatment | Bevacizumab |
Phase | Phase2 |
Recruitment status | Completed |
Title | Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG) Integrated With Bevacizumab for Patients With Recurrent/Refractory Ovarian Cancer Participating in Study CL-PTL 105 |
Year | 2012 |
Country | United States |
Company sponsor | Gradalis, Inc |
Other ID(s) | CL-PTL 112 |
Cohort 1 | |||||||||||||
|